Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Partners with Large Pharmaceutical Company to Drive Advancements to the GastroPlus Mechanistic Oral Absorption Model


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new

Simulations Plus Enters New Collaboration with Leading Animal Health Company: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Enters New Collaboration with Leading Animal Health Company


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new

Simulations Plus to Present at Sidoti Winter Small Cap Investor Conference: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus to Present at Sidoti Winter Small Cap Investor Conference


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn

NanoString Reports Inducement Grant Under Nasdaq Listing Rules: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Reports Inducement Grant Under Nasdaq Listing Rules


NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today reported, as required by Nasdaq Stock Market Rules, an equity

STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Announces Preliminary Fourth Quarter and Full Year 2021 Results


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today provided preliminary results for the

Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.


Owens & Minor, Inc. (“Owens & Minor”) (NYSE: OMI) and Apria, Inc. (“Apria”) (Nasdaq: APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor

NanoString Announces Commercial Leadership Transition: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Announces Commercial Leadership Transition


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced a commercial leadership transition. Chad Brown, who

NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2021: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString Provides Preliminary Financial and Operational Highlights for Fourth Quarter and FY 2021


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for

Simulations Plus Reports First Quarter Fiscal 2022 Financial Results: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Reports First Quarter Fiscal 2022 Financial Results


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first

Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Lixoft Adds New Bioequivalence Module in MonolixSuite® Version 2021R1


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Lixoft division, a leading

NanoString to Webcast Presentation from the 40th Annual JP Morgan Healthcare Conference: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString to Webcast Presentation from the 40th Annual JP Morgan Healthcare Conference


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a

Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Sets Date for First Quarter Fiscal Year 2022 Earnings Release and Conference Call


Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close of the

Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has extended its

Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope


Simulations Plus, Inc. (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to the

Owens & Minor to Present at Bank of America Leveraged Finance Conference: https://mms.businesswire.com/media/20211103005246/en/922805/5/O%26M_LogoTM_hi-res.jpg
Owens & Minor to Present at Bank of America Leveraged Finance Conference


Owens & Minor, Inc. (NYSE-OMI), a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services, today announced that Andy

Sichern Sie sich den Gaming-Thron: BigBuy Home Silla Gaming Genesis Nitro 650 zum unschlagbaren Preis!: https://m.media-amazon.com/images/I/41gzkGNRoPL._AC_SL1000_.jpg
Sichern Sie sich den Gaming-Thron: BigBuy Home Silla Gaming Genesis Nitro 650 zum unschlagbaren Preis!
Sichern Sie sich den Gaming-Thron: BigBuy Home Silla Gaming Genesis Nitro 650 zum unschlagbaren Preis! Jetzt ansehen Bist du ein leidenschaftlicher Gamer oder verbringst du aus beruflichen Gründen
DGAP-News: MicroVision to Participate in Virtual Fireside Chat Webcast and One-On-One Investor Meetings on April 13, 2022
DGAP-News: MicroVision to Participate in Virtual Fireside Chat Webcast and One-On-One Investor Meetings on April 13, 2022
DGAP-News: MicroVision to Participate in Virtual Fireside Chat Webcast and One-On-One Investor Meetings on April 13, 2022
DGAP-News: MicroVision Inc.: MicroVision Appoints Jeffrey Herbst to Board of Directors
DGAP-News: MicroVision Inc.: MicroVision Appoints Jeffrey Herbst to Board of Directors
DGAP-News: MicroVision Inc.: MicroVision Appoints Jeffrey Herbst to Board of Directors
DGAP-News: MicroVision's Leaders to Participate in Webcast Fireside Chat with Cantor Fitzgerald Analyst on March 22, 2022
DGAP-News: MicroVision's Leaders to Participate in Webcast Fireside Chat with Cantor Fitzgerald Analyst on March 22, 2022
DGAP-News: MicroVision's Leaders to Participate in Webcast Fireside Chat with Cantor Fitzgerald Analyst on March 22, 2022
DGAP-News: MicroVision Inc.: MicroVision Announces Fourth Quarter and Full Year 2021 Results
DGAP-News: MicroVision Inc.: MicroVision Announces Fourth Quarter and Full Year 2021 Results
DGAP-News: MicroVision Inc.: MicroVision Announces Fourth Quarter and Full Year 2021 Results
DGAP-News: MicroVision Inc.: MicroVision to Announce Fourth Quarter and Full Year 2021 Results on February 24, 2022
DGAP-News: MicroVision Inc.: MicroVision to Announce Fourth Quarter and Full Year 2021 Results on February 24, 2022
DGAP-News: MicroVision Inc.: MicroVision to Announce Fourth Quarter and Full Year 2021 Results on February 24, 2022
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
DGAP-News: MicroVision Inc.: MicroVision to Participate in LiDAR Sensor Standards Consortium
DGAP-News: MicroVision Inc.: MicroVision to Participate in LiDAR Sensor Standards Consortium
DGAP-News: MicroVision Inc.: MicroVision to Participate in LiDAR Sensor Standards Consortium
2 Stocks Providing Medical Insurance for Your Pets: https://www.marketbeat.com/logos/articles/med_20240519155501_chart-trup.jpg
2 Stocks Providing Medical Insurance for Your Pets

The pandemic triggered a surge in pet ownership as social distancing and lockdowns resulted in the need for companionship for many individuals and families. Anyone who owns a dog or cat can

Novo Nordisk Arms Wegovy to Be a Triple Threat: https://www.marketbeat.com/logos/articles/med_20240414165029_charts-nvo.jpg
Novo Nordisk Arms Wegovy to Be a Triple Threat

Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S (NYSE: NVO). Originally purposed for Type 2 diabetes, the skyrocketing off-label